UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California

Journal of acquired immune deficiency syndromes (1999), 2017-12, Vol.76 (5), p.501-511

2017

Volltextzugriff (PDF)

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

AIDS (London), 2016-07, Vol.30 (12), p.1973-1983

2016

Volltextzugriff (PDF)

Drug Concentrations in Hair and Dried Blood Spots as Preexposure Prophylaxis Adherence Metrics During Pregnancy and Postpartum

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.689-695

2024

Volltextzugriff (PDF)

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS (London), 2024-06, Vol.38 (7), p.983-991

2024

Volltextzugriff (PDF)

The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen

AIDS (London), 2020-05, Vol.34 (6), p.877-881

2020

Volltextzugriff (PDF)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide

AIDS (London), 2022-12, Vol.36 (15), p.2225-2227

2022

Volltextzugriff (PDF)

Tenofovir and bone health

Current opinion in HIV & AIDS, 2016-05, Vol.11 (3), p.326-332

2016

Volltextzugriff (PDF)

Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV

AIDS research and human retroviruses, 2022-06, Vol.38 (6), p.472-479

2022

Volltextzugriff (PDF)

Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project

AIDS (London), 2019-04, Vol.33 (5), p.867-872

2019

Volltextzugriff (PDF)

Is tenofovir disoproxil fumarate associated with weight loss?

AIDS (London), 2021-12, Vol.35 (Suppl 2), p.S189-S195

2021

Volltextzugriff (PDF)

Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy

Journal of acquired immune deficiency syndromes (1999), 2024-03, Vol.95 (3), p.260-267

2024

Volltextzugriff (PDF)

A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.696-705

2024

Volltextzugriff (PDF)

Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure

Journal of acquired immune deficiency syndromes (1999), 2022-05, Vol.90 (1), p.27-32

2022

Volltextzugriff (PDF)

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis

Journal of the International AIDS Society, 2024-09, Vol.27 (9), p.e26358-n/a

2024

Volltextzugriff (PDF)

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

Journal of acquired immune deficiency syndromes (1999), 2021-09, Vol.88 (1), p.86-95

2021

Volltextzugriff (PDF)

A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women

Journal of acquired immune deficiency syndromes (1999), 2019-07, Vol.81 (3), p.311-318

2019

Volltextzugriff (PDF)

Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study

Journal of the International AIDS Society, 2019-07, Vol.22 (7), p.e25338-n/a

2019

Volltextzugriff (PDF)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study

Journal of the International AIDS Society, 2021-04, Vol.24 (4), p.e25702-n/a

2021

Volltextzugriff (PDF)

Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings

AIDS (London), 2020-02, Vol.34 (2), p.255-260

2020

Volltextzugriff (PDF)

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

Journal of the International AIDS Society, 2019-11, Vol.22 (11), p.e25405-n/a

2019

Volltextzugriff (PDF)

Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure

AIDS (London), 2023-06, Vol.37 (7), p.1109-1113

2023

Volltextzugriff (PDF)

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Current opinion in HIV & AIDS, 2016-01, Vol.11 (1), p.49-55

2016

Volltextzugriff (PDF)

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women

Nature medicine, 2018-04, Vol.24 (4), p.491-496

2018

Volltextzugriff (PDF)

Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV

AIDS (London), 2020-07, Vol.34 (8), p.1161-1170

2020

Volltextzugriff (PDF)

Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations

Journal of acquired immune deficiency syndromes (1999), 2020-06, Vol.84 (2), p.149-152

2020

Volltextzugriff (PDF)

1 – 25 von 1.535

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.495)
Mit Volltextzugriff
(988)

Publikationsform

Artikel
(1.531)
Buchkapitel
(4)

Sprache

Englisch
(1.535)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

Drug Concentrations in Hair and Dried Blood Spots as Preexposure Prophylaxis Adherence Metrics During Pregnancy and Postpartum

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide

Tenofovir and bone health

Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV

Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project

Is tenofovir disoproxil fumarate associated with weight loss?

Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy

A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention

Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women

Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study

Weight gain before and after switch from TDF to TAF in a U.S. cohort study

Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women

Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV

Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations

Aktive Filter

Suchergebnisse filtern